Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Feb 6:2019:1951030.
doi: 10.1155/2019/1951030. eCollection 2019.

Reversible MR Findings in Marchiafava-Bignami Disease

Affiliations
Case Reports

Reversible MR Findings in Marchiafava-Bignami Disease

Carmine Franco Muccio et al. Case Rep Neurol Med. .

Abstract

Marchiafava-Bignami Disease (MBD) is a toxic demyelinating disease often diagnosed in chronic alcoholics. The disease process typically involves the corpus callosum and clinically presents with various manifestations resulting in MBD type A and type B on the basis of clinical condition, extent of callosal involvement and extracallosal involvement at brain magnetic resonance imaging (MRI), and prognosis. The death rate is high. We report a patient affected by MBD type B, who presented an isolated reversible splenial lesion at brain MRI and achieved a favorable recovery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MRI studies at onset (a-c) and 1-month follow-up (d-f). Sagittal FSE-T2 image (a) demonstrating hyperintense regions in the splenium of the corpus callosum (white arrow). DWI (b) image shows its hyperintense signal (black arrow) and ADC map (c) shows its reduced diffusivity. Corresponding sagittal FSE-T2 image (d) and DWI images (e) showing normal signal in the splenium of the corpus callosum (white arrow head and black arrow head, respectively) where the ADC map (f) shows normalization of water diffusivity.

Similar articles

Cited by

References

    1. Pinter G., Borbely K., Peter L. Marchiafava-Bignami disease (Case-report) Neuropsychopharmacol Hung International Journal. 2016;18(2):115–118. - PubMed
    1. Marjama J., Yoshino M. T., Reese C. Marchiafava-Bignami Disease. Journal of Neurogenetics. 1994;4(2):106–109. doi: 10.1111/jon199442106. - DOI - PubMed
    1. Caulo M., Briganti C., Notturno F., et al. Non-Alcoholic Partially Reversible Marchiafava-Bignami Disease: Review and Relation with Reversible Splenial Lesions. The Neuroradiology Journal. 2009;22(1):35–40. doi: 10.1177/197140090902200106. - DOI - PubMed
    1. Takanashi J.-I., Imamura A., Hayakawa F., Terada H. Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) Journal of the Neurological Sciences. 2010;292(1-2):24–27. doi: 10.1016/j.jns.2010.02.013. - DOI - PubMed
    1. Kakkar C., Prakashini K., Polnaya A. Acute Marchiafava-Bignami disease: Clinical and serial MRI correlation. BMJ Case Reports. 2014 - PMC - PubMed

Publication types

LinkOut - more resources